StockUS listing USPYCXFPINKHealthcareEarnings Deterioration

PYCXF(PYCXF) Stock Analysis | Healthcare

USD --+0.00%
Reward38Moderate
Risk46Moderate
75%Data
Thin -231% profit margin · Revenue down 25% YoY
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 1.19Bn
Reward Ratingⓘ38 Moderate reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ46 Moderate risk assessment · 75% data coverage
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on PYCXF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is PYCXF?

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.

AI Brief Pro

The brief on PYCXF

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is PYCXF?

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atrophy, which is in clinical studies; PYC-002, a drug program for the treatment of severe neurodevelopmental disorder named Phelan-McDermid Syndrome, which is in pre-clinical studies; and PYC-003 to treat autosomal dominant polycystic kidney disease, which is in early-stage clinical trials. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 1.19B.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (38)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.887
Insider Activity
12M windowNo data
No insider activity data available for this ticker.